+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 8Years - 16Years
All Genders
ID05745532

Evaluating Safety and Effectiveness of Beta-globin Restored Stem Cell Therapy for Children and Teens with Beta-Thalassemia Major

Led by Shenzhen Hemogen · Updated on 2024-11-29

10

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of b2-globin restored autologous hematopoietic stem cells in patients with b2-thalassemia major, a condition requiring regular blood transfusions. This early phase 1, open-label study focuses on restoring b2-globin expression to improve patient outcomes. The study is sponsored by Shenzhen Hemogen and targets children and adolescents aged 8 to 16 years with transfusion-dependent b2-thalassemia major. Participants will have their own hematopoietic stem cells collected and modified using the LentiHBBT87Q system to restore b2-globin production. After a conditioning process, these modified stem cells will be reinfused into the patients. Ten subjects aged 8 to 16 years will receive this treatment and be followed for two years to observe effects and safety. During the study, researchers will monitor adverse events, survival rates, engraftment success, viral replication, and viral integration over 24 months. Secondary measures include monitoring viral copy number in blood cells, adult hemoglobin expression, and changes in blood transfusion needs. Participants will undergo regular medical visits, treatments, and assessments throughout the two-year follow-up period to collect comprehensive data on treatment impact and safety.

CONDITIONS

Brief Title

Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients

Research Team

H

Haigang Sun

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here